Literature DB >> 12548079

Electrophysiologic characterization of dronedarone in guinea pig ventricular cells.

Patrick Gautier1, Eric Guillemare, Aline Marion, Jean-Philippe Bertrand, Yves Tourneur, Dino Nisato.   

Abstract

The electrophysiological properties of dronedarone (SR33589), a noniodinated amiodarone-like agent, were studied on action potential (AP) and contraction of papillary muscle and on membrane ionic currents, Ca2+ transient, and shortening of ventricular cells of the guinea pig heart. In multicellular preparations, dronedarone (3, 10, and 30 microM) decreased maximum rate of rise of AP (dV/dt max) with a concentration- and frequency-dependent relationship; resting potential was not modified and AP amplitude was decreased only at 30 microM. The effects of dronedarone on AP durations (APDs) at different percentages of repolarization were not significantly changed, except for a slight decrease in APD30 and APD50 at the highest concentration. In isolated ventricular myocytes, dronedarone inhibited rapidly activating delayed-rectifier K+ current (I(Kr)) (median inhibitory concentration [IC50] </= 3 microM voltage-independent); slowly activating delayed-rectifier K+ current (I(Ks)) (IC50 approximately/= 10 microM voltage-dependent and time-, frequency-, or use-independent); and inward rectifier potassium current (I(K1)) (IC50 >/= 30 microM). Dronedarone blocked L-type Ca2+ current (I(Ca(L))) (IC50 = 0.18 +/- 0.018 microM at a stimulation frequency of 0.033 Hz) in a use- and frequency-dependent manner. Simultaneously to these electrophysiological effects, dronedarone reduced contraction amplitudes of papillary muscle and decreased Ca2+ transient and shortening of ventricular myocytes. The results show that dronedarone is a multichannel blocker because it decreases dV/dt max (I(Na)), I(Ca(L)), I(Kr), I(Ks), and I(K1). These effects are accompanied by a reduction in free intracellular calcium and contraction amplitudes. Dronedarone does not significantly change APD whatever the stimulation frequency. Our data demonstrate that the acute electrophysiological characteristics of dronedarone, despite absence of iodine in its molecular structure, are very similar to those of amiodarone in cardiac ventricle.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12548079     DOI: 10.1097/00005344-200302000-00007

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  34 in total

1.  Effect of dronedarone on Na+, Ca2+ and HCN channels.

Authors:  Roman Bogdan; Heinz Goegelein; Hartmut Ruetten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-01-29       Impact factor: 3.000

Review 2.  New developments in atrial antiarrhythmic drug therapy.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Nat Rev Cardiol       Date:  2010-03       Impact factor: 32.419

3.  Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria.

Authors:  Alexander Burashnikov; Luiz Belardinelli; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2010-05-15       Impact factor: 6.343

4.  Depolarization-induced automaticity in rat ventricular cardiomyocytes is based on the gating properties of L-type calcium and slow Kv channels.

Authors:  Dirk L Ypey; Wilbert P M van Meerwijk; Soban Umar; Daniel A Pijnappels; Martin J Schalij; Arnoud van der Laarse
Journal:  Eur Biophys J       Date:  2012-10-23       Impact factor: 1.733

5.  Dronedarone prevents microcirculatory abnormalities in the left ventricle during atrial tachypacing in pigs.

Authors:  A Bukowska; M Hammwöhner; A Sixdorf; L Schild; I Wiswedel; F-W Röhl; C Wolke; U Lendeckel; C Aderkast; S Bochmann; R K Chilukoti; J Mostertz; P Bramlage; A Goette
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 6.  Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.

Authors:  Ahmed M A Adlan; Gregory Y H Lip
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

7.  Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels.

Authors:  Dierk Thomas; Sven Kathofer; Wei Zhang; Kezhong Wu; Anna-Britt Wimmer; Edgar Zitron; Volker A W Kreye; Hugo A Katus; Wolfgang Schoels; Christoph A Karle; Johann Kiehn
Journal:  Br J Pharmacol       Date:  2003-09-29       Impact factor: 8.739

Review 8.  Novel approaches for pharmacological management of atrial fibrillation.

Authors:  Joachim R Ehrlich; Stanley Nattel
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 9.  Impact of dronedarone in atrial fibrillation and flutter on stroke reduction.

Authors:  Christine Benn Christiansen; Christian Torp-Pedersen; Lars Køber
Journal:  Clin Interv Aging       Date:  2010-04-07       Impact factor: 4.458

Review 10.  Dronedarone for atrial fibrillation: a new therapeutic agent.

Authors:  Pawan D Patel; Rohit Bhuriya; Dipal D Patel; Bhaskar L Arora; Param P Singh; Rohit R Arora
Journal:  Vasc Health Risk Manag       Date:  2009-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.